Evidence map›Paper›PMID 39233763›Full record

ArticleEvolution, medicine, and public health2024

Germline mutation rate predicts cancer mortality across 37 vertebrate species.

Stefania E Kapsetaki, Zachary T Compton, Walker Mellon, Orsolya Vincze, Mathieu Giraudeau, Tara M Harrison, Lisa M Abegglen, Amy M Boddy, Carlo C Maley, Joshua D Schiffman

Abstract read
In one paragraph

Article in Evolution, medicine, and public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Elephant and the Spandrel.Evolution, medicine, and public health · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stefania E KapsetakiArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.ORCID https://orcid.org/0000-0002-9999-8573
Zachary T ComptonArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.
Walker MellonArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.
Orsolya VinczeEvolutionary Ecology Group, Hungarian Department of Biology and Ecology, Babeș-Bolyai University, Cluj-Napoca, Romania.
Mathieu GiraudeauLittoral Environnement Et Sociétés (LIENSs), UMR7266, CNRS Université de La Rochelle, 2 rue Olympe de Gouges, 17042 La Rochelle Cedex, France.ORCID https://orcid.org/0000-0001-8563-1810
Tara M HarrisonArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.
Lisa M AbegglenArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.ORCID https://orcid.org/0000-0003-3607-3001
Amy M BoddyArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.
Carlo C MaleyArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.ORCID https://orcid.org/0000-0002-0745-7076
Joshua D SchiffmanArizona Cancer Evolution Center, Arizona State University, Tempe, AZ, USA.

Funding

Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY · 2018 to 2023
$11.4M
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
Modeling Neoplastic Progression in Barrett's Esophagus - Renewal -2R01CA140657 · NCI · WISTAR INSTITUTE · PI Carlo Maley · 2009 to 2026
$5.0M
T32 Cancer Prevention and Control Training Program Addressing Health DisparitiesT32CA272303 · NCI · UNIVERSITY OF ARIZONA · PI Terry A Badger, Gloria D. Coronado · 2023 to 2026
$1.1M
A cell-cycle induced genetic recorder for simultaneous recovery of cell divisions and lineageR21CA257980 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MALEY, CARLO, WEISS, RON · 2022 to 2023
$576k
NCI NIH HHS R01 CA140657NCI NIH HHS R21 CA257980NCI NIH HHS T32 CA272303NCI NIH HHS U2C CA233254NCI NIH HHS U54 CA217376
6 · The paper itself

Abstract

Background and objectives: Cancer develops across nearly every species. However, cancer occurs at unexpected and widely different rates throughout the animal kingdom. The reason for this variation in cancer susceptibility remains an area of intense investigation. Cancer evolves in part through the accumulation of mutations, and therefore, we hypothesized that germline mutation rates would be associated with cancer prevalence and mortality across species. Methodology: We collected previously published data on germline mutation rate and cancer mortality data for 37 vertebrate species. Results: Germline mutation rate was positively correlated with cancer mortality (P-value = 0.0008; R2 = 0.13). Controlling for species' average parental age, maximum longevity, adult body mass or domestication did not improve the model fit (the change (Δ) in Akaike Information Criterion (AIC) was less than 2). However, this model fit was better than a model controlling for species trophic level (ΔAIC > 2). Conclusions and implications: The increased death rate from cancer in animals with increased germline mutation rates may suggest underlying hereditary cancer predisposition syndromes similar to those diagnosed in human patients. Species with higher germline mutation rates may benefit from close monitoring for tumors due to increased genetic risk for cancer development. Early diagnoses of cancer in these species may increase their chances of overall survival, especially for threatened and endangered species.

Indexed as

animalsgerm cell mutationsmalignancytumor

Identifiers

PMID39233763
PMCPMC11372239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.